PMID- 38196830
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240111
IS  - 1178-7058 (Print)
IS  - 1178-7058 (Electronic)
IS  - 1178-7058 (Linking)
VI  - 17
DP  - 2024
TI  - Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic 
      Kidney Disease: A Middle East and Africa Perspective.
PG  - 1-16
LID - 10.2147/IJNRD.S430532 [doi]
AB  - Chronic kidney disease (CKD) is a major public health concern in the Middle East 
      and Africa (MEA) region and a leading cause of death in patients with type 2 
      diabetes mellitus (T2DM) and hypertension. Early initiation of sodium-glucose 
      cotransporter - 2 inhibitors (SGLT-2i) and proper sequencing with 
      renin-angiotensin-aldosterone system inhibitors (RAASi) in these patients may 
      result in better clinical outcomes due to their cardioprotective properties and 
      complementary mechanisms of action. In this review, we present guideline-based 
      consensus recommendations by experts from the MEA region, as practical algorithms 
      for screening, early detection, nephrology referral, and treatment pathways for 
      CKD management in patients with hypertension and diabetes mellitus. This study 
      will help physicians take timely and appropriate actions to provide better care 
      to patients with CKD or those at high risk of CKD.
CI  - (c) 2024 Elkeraie et al.
FAU - Elkeraie, Ahmed Fathi
AU  - Elkeraie AF
AUID- ORCID: 0000-0002-0305-2290
AD  - Department of Internal Medicine and Nephrology, Alexandria University, 
      Alexandria, Egypt.
FAU - Al-Ghamdi, Saeed
AU  - Al-Ghamdi S
AD  - Department of Medicine, College of Medicine, King Abdulaziz University, Jeddah, 
      Saudi Arabia.
FAU - Abu-Alfa, Ali K
AU  - Abu-Alfa AK
AD  - Department of Internal Medicine, Division of Nephrology and Hypertension, 
      American University of Beirut, Beirut, Lebanon.
FAU - Alotaibi, Torki
AU  - Alotaibi T
AD  - Transplant Nephrology, Hamed Al-Essa Organ Transplant Center, Sabah Health 
      Region, Kuwait City, Kuwait.
FAU - AlSaedi, Ali Jasim
AU  - AlSaedi AJ
AD  - Department of Nephrology, College of Medicine, University of Baghdad, Nephrology 
      and Transplantation Center, Medical City Complex, Baghdad, Iraq.
FAU - AlSuwaida, Abdulkareem
AU  - AlSuwaida A
AD  - Department of Medicine, King Saud University, Riyadh, Saudi Arabia.
FAU - Arici, Mustafa
AU  - Arici M
AD  - Department of Nephrology, Faculty of Medicine, Hacettepe University, Altindag, 
      Ankara, Turkey.
FAU - Ecder, Tevfik
AU  - Ecder T
AD  - Department of Medicine, Istinye University; Division of Nephrology, Topkapi, 
      Istanbul, Turkey.
FAU - Ghnaimat, Mohammad
AU  - Ghnaimat M
AD  - Department of Nephrology, Specialty Hospital, Jaber Ibn Hayyan St. Shmeisani, 
      Amman, Jordan.
FAU - Hafez, Mohamed Hany
AU  - Hafez MH
AD  - Department of Nephrology and Medicine, Cairo University, Cairo, Egypt.
FAU - Hassan, Mohamed H
AU  - Hassan MH
AD  - Department of Medicine, Sheikh Khalifa Medical City, Abu Dhabi, United Arab 
      Emirates.
FAU - Sqalli, Tarik
AU  - Sqalli T
AD  - Department of Nephrology, Moroccan Society of Nephrology, Casablanca, Morocco.
LA  - eng
PT  - Journal Article
DEP - 20240103
PL  - New Zealand
TA  - Int J Nephrol Renovasc Dis
JT  - International journal of nephrology and renovascular disease
JID - 101550217
PMC - PMC10771977
OTO - NOTNLM
OT  - chronic kidney disease
OT  - nephrology referral
OT  - screening
OT  - sodium-glucose cotransporter-2 inhibitors
COIS- Ahmed Fathi ElKeraie received speaker honoraria from AstraZeneca, Novartis, 
      Boehringer Ingelheim, Sanofi, Johnson and Johnson, Amgen, Roche, Astellas Pharma, 
      Inc., and Fresenius Kabi. Saeed Al-Ghamdi received speaker honoraria from 
      AstraZeneca, Astellas Pharma Inc., AbbVie, and Vifor Pharmaceuticals. Ali K 
      Abu-Alfa received speaking and consulting honoraria and/or research support from 
      Astellas Pharma Inc., AstraZeneca, Baxter Healthcare, Boehringer Ingelheim, 
      Fresenius Medical Care, Novartis and Sanofi-Aventis. His contribution to this 
      publication was made in his individual capacity and not as part of his American 
      University of Beirut or any other organization or institution duties or 
      responsibilities. Mustafa Arici received speaker honoraria from Amgen, Astellas 
      Pharma Inc., AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo 
      Nordisk, Sandoz and Sanofi. He also received honoraria as an advisory board 
      member for Astellas Pharma Inc., AstraZeneca, Bayer, Boehringer Ingelheim, MSD, 
      and Novo Nordisk. Tevfik Ecder received speaker honoraria from Amgen, Astellas 
      Pharma Inc., AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Recordati, 
      Sandoz and Sanofi. The authors report no other conflicts of interest in this 
      work.
EDAT- 2024/01/10 06:42
MHDA- 2024/01/10 06:43
PMCR- 2024/01/03
CRDT- 2024/01/10 03:43
PHST- 2023/07/18 00:00 [received]
PHST- 2023/11/28 00:00 [accepted]
PHST- 2024/01/10 06:43 [medline]
PHST- 2024/01/10 06:42 [pubmed]
PHST- 2024/01/10 03:43 [entrez]
PHST- 2024/01/03 00:00 [pmc-release]
AID - 430532 [pii]
AID - 10.2147/IJNRD.S430532 [doi]
PST - epublish
SO  - Int J Nephrol Renovasc Dis. 2024 Jan 3;17:1-16. doi: 10.2147/IJNRD.S430532. 
      eCollection 2024.